One dose of H1N1 vaccine protective
Results of the first H1N1 swine flu vaccine trials show that one dose of the vaccine produces strong protection from swine flu. H1N1 swine flu vaccine trials, conducted on 100 healthy volunteers, aged between 18 and 50, by the University of Leicester and Leicester Hospitals revealed that two doses produced the highest level of H1N1 flu protection, but one dose single dose was enough to produce strong antibodies against the disease.
According to Dr Iain Stephenson, who led the trial, "The findings showed that it is possible to induce protective antibody against A(H1N1) infection within two weeks of administration of a single low-dose adjuvanted vaccine."
The study looked at protection from the H1N1 vaccine, and time between injections, using one or two doses of 7.5μg MF-59 adjuvanted surface-antigen A/California/2009 vaccine taken from cell cultures in the lab, finding that after one dose a protective antibody developed to protect from H1N1 (swine) flu.
Large trials of the H1N1 swine flu vaccine are underway worldwide. “Timings on when the vaccine will be available to governments will depend on the results of these clinical trials, and approvals by regulatory authorities”, says Dr. Stephenson.
Studies including more than 6000 adults and children are also being conducted, using traditional egg based, and cell cultured H1N1 swine flu vaccine to measure tolerability and immune response.
So far, the only side effect of H1N1 swine flu vaccine is pain at the site of injection. According to results of the clinical trial, swine flu vaccine has been well tolerated, producing strong immunity against H1N1 flu with a single dose.
University of Leicester